Pakistan Pharmas Shut Punjab Plants To Protest Drug-Regulator Ruling
This article was originally published in PharmAsia News
Pakistan's pharmaceutical industry has united in shutting its doors in the province of Punjab to protest a decision by the nation's central drug laboratory to issue a forensic report blaming the makers for deaths tied to Tyno Syrup.
You may also be interested in...
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.